Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers

被引:25
作者
Fujimoto, Yukie [1 ]
Watanabe, Takahiro [2 ]
Hida, Akira I. [3 ]
Higuchi, Tomoko [1 ]
Miyagawa, Yoshimasa [1 ]
Ozawa, Hiromi [1 ]
Bun, Ayako [1 ]
Fukui, Reiko [1 ]
Sata, Atsushi [1 ]
Imamura, Michiko [1 ]
Hirota, Seiichi [2 ]
Miyoshi, Yasuo [1 ]
机构
[1] Hyogo Coll Med, Dept Surg, Div Breast & Endocrine Surg, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Dept Surg Pathol, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[3] Matsuyama Shimin Hosp, Dept Pathol, 2-6-5 Otemachi, Matsuyama, Ehime 7900067, Japan
关键词
Breast cancer; Tumor-infiltrating lymphocytes; Ki67; Prognosis; INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; HIGHLIGHTS; CHEMOTHERAPY; SUBTYPES;
D O I
10.1007/s12282-019-00977-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been established in breast cancers with estrogen receptor (ER)-negative and human epithelial growth factor receptor 2 (HER2)-negative or HER2-positive subtypes; however, its utility concerning the ER + /HER2-subtype remains unclear. Methods We evaluated the prognostic value of TILs by analyzing 717 invasive breast cancer operation cases. TILs were classified into three groups based on the proportion of area within the tumor: low (< 10%), intermediate (10-50%), and high (> 50%). Disease-free survival (DFS) and overall survival (OS) were calculated according to TIL levels. Results Although there was no significant association between TIL levels and DFS or OS in all patients, high TILs were significantly associated with favorable DFS in Ki67-high (n = 238, p = 0.035) but not in Ki67-low (n = 470, p = 0.46) breast cancers. Multivariable analysis showed that high TILs were a significant and independent factor for DFS (HR 0.34; 95% CI 0.10-0.87; p = 0.023) among the Ki67-high group. In the ER + /HER2 - subtype, high-TILs showed favorable DFS in the Ki67-high group, although this was not statistically significant (p = 0.48); in contrast, unfavorable DFS was observed in the Ki67-low group (p = 0.027). Conclusions In Ki67-high breast cancers, high TILs were associated with favorable DFS, irrespective of subtype, but increasing TIL levels correlated with worse DFS in the Ki67-low group with the ER + /HER2 -subtype. These results highlight variation in TIL prognostic significance between Ki67-high and -low breast cancers, particularly for the ER + /HER2 - subtype.
引用
收藏
页码:738 / 747
页数:10
相关论文
共 50 条
  • [31] Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
    Akira I. Hida
    Yasuaki Sagara
    Daisuke Yotsumoto
    Shuichi Kanemitsu
    Junko Kawano
    Shinichi Baba
    Yoshiaki Rai
    Yumi Oshiro
    Kenjiro Aogi
    Yoshiaki Sagara
    Yasuyo Ohi
    Breast Cancer Research and Treatment, 2016, 158 : 1 - 9
  • [32] Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
    Brodsky, Alexander S.
    Xiong, Jinjun
    Yang, Dongfang
    Schorl, Christoph
    Fenton, Mary Anne
    Graves, Theresa A.
    Sikov, William M.
    Resnick, Murray B.
    Wang, Yihong
    BMC CANCER, 2016, 16
  • [33] High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer
    Oshi, Masanori
    Angarita, Fernando A.
    Tokumaru, Yoshihisa
    Yan, Li
    Matsuyama, Ryusei
    Endo, Itaru
    Takabe, Kazuaki
    CANCERS, 2020, 12 (12) : 1 - 15
  • [34] Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature
    Mooghal, Mehwish
    Khan, Muhammad Ali Akbar
    Samar, Mirza Rameez
    Shaikh, Hafsa
    Valimohammad, Azmina Tajdin
    Idrees, Romana
    Rashid, Yasmin Abdul
    Sattar, Abida K.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2024, 18
  • [35] Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors
    Arima, Nobuyuki
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Nakano, Masahiro
    Fujisue, Mamiko
    Nishiyama, Yasuyuki
    Toyozumi, Yasuo
    ONCOLOGY LETTERS, 2019, 17 (01) : 616 - 622
  • [36] Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer
    Tokiniwa, Hideaki
    Horiguchi, Jun
    Takata, Daisuke
    Kikuchi, Mami
    Rokutanda, Nana
    Nagaoka, Rin
    Sato, Ayako
    Odawara, Hiroki
    Tozuka, Katsunori
    Oyama, Tetsunari
    Takeyoshi, Izumi
    BREAST CANCER, 2012, 19 (04) : 309 - 314
  • [37] Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Iwamoto, Takayuki
    Kelly, Catherine
    Mizoo, Taeko
    Nogami, Tomohiro
    Motoki, Takayuki
    Shien, Tadahiko
    Taira, Naruto
    Hayashi, Naoki
    Niikura, Naoki
    Fujiwara, Toshiyoshi
    Doihara, Hiroyoshi
    Matsuoka, Junji
    CLINICAL BREAST CANCER, 2016, 16 (02) : 95 - 100
  • [38] Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study
    Kwak, Youngji
    Jang, Sung Yoon
    Choi, Joon Young
    Lee, Hyunjun
    Shin, Dong Seung
    Park, Yeon Hee
    Kim, Ji-Yeon
    Ahn, Jin-Seok
    Chae, Byung Joo
    Yu, Jonghan
    Lee, Jeong Eon
    Kim, Seok Won
    Nam, Seok Jin
    Ryu, Jai Min
    CANCERS, 2023, 15 (13)
  • [39] Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy
    Honma, Naoko
    Horii, Rie
    Iwase, Takuji
    Saji, Shigehira
    Younes, Mamoun
    Ito, Yoshinori
    Akiyama, Futoshi
    BREAST CANCER, 2015, 22 (01) : 71 - 78
  • [40] Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers
    Lee, So Jeong
    Hwang, Cheong-Soo
    Kim, Young-Keum
    Lee, Hyun Jung
    Ahn, Sang-Jeong
    Shin, Nari
    Lee, Jung Hee
    Shin, Dong Hoon
    Choi, Kyung Un
    Park, Do Youn
    Lee, Chang Hun
    Huh, Gi Young
    Sol, Mi Young
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Jee Yeon
    Kim, Ahrong
    CANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 313 - 321